Moreover, in a breast cancer xenograft model, VEGF was found to be elevated in the trastuzumab-resistant group, and sensitivity to trastuzumab was restored upon treatment with bevacizumab (Rugo, 2004). This evidence concerns the gene VEGFA and breast carcinoma.